Lead Indications For Commercialization

Oncology Asset:
BMX-001

  • Mechanisms of action:
      • Tumor Inhibition
      • Protection of Normal Tissue by Inhibition of NF-kB & Activation of NrF2
  • Strong CMC and Safety/Toxicology Position
      • 72 month stability at Room Temperature
  • No major toxicity
      • most common AE in humans is a grade 1 injection site reaction
      • minimal SAEs
  • Intellectual property
      • Strong IP with additional information available under terms of confidentiality
  • Clinical Trials- data collection limited to long-term follow up
      • High Grade Glioma -Phase 1/2
      • Head and Neck Cancer – Phase 1/2
  • Enrolling Clinical Trials – Phase 2
      • Multiple Brain Metastasis (i.e. lung cancer, breast cancer)
      • Anal Carcinoma
      • Above clinical trials funded by NCI SBIRs and University of Nebraska
  • Planned Clinical Trials – Phase 2
      • Rectal Cancer, single-site study, IND open
      • Head and Neck Cancer Randomized
  • Pre-clinical data supports line extensions to prostate cancer and ovarian cancer
  • The randomized Phase 2 clinical trial of 160 subjects in high-grade glioma is closed for enrollment.  Enrollment was completed and patients are currently being followed for long term follow up.
  • Orphan designation for treatment of gliomas and Fast Track Designation for HGG program has been granted by the FDA.
Oncology
Dermatology

Dermatology Asset:
BMX-010

Indications

  • Atopic Dermatitis
  • Pruritus
  • Rosacea

BioMimetix has completed a Phase 1 clinical trial in pruritus, atopic dermatitis and psoriasis which provided:

  • Establishment of a therapeutic dose with a clean safety profile.
  • Reduction/clearing of inflammatory skin lesions.
  • Rapid reduction in pruritus.
  • No significant systemic absorption.

Additional information available under terms of confidentiality.

A development and commercialization partner is being sought to expedite Phase 2 clinical trials and lead market entry activities.

 

More information is available under confidentiality terms 

For investment inquiries, please contact James Crapo, MD at contact@bmxpharma.com

BioMimetix attends BIO and JP Morgan meetings each year.

Contact Us

4 + 4 =

Share This Webpage

Share this page with your friends!